Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Manufacturers: Comprehensive Analysis Of Production Technologies, Quality Standards, And Industrial Applications

NOV 17, 202667 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine phosphate (phosphocreatine, N-phosphorylcreatine) represents a critical high-energy phosphate compound extensively utilized in cardiovascular therapeutics and sports nutrition. As a myocardial protective agent with efficacy approximately 316-fold greater than fructose-1,6-diphosphate, creatine phosphate has driven substantial industrial interest among manufacturers worldwide 10. This article provides an in-depth examination of manufacturing methodologies, quality control parameters, regulatory considerations, and emerging production technologies relevant to creatine phosphate manufacturers operating at commercial scale.
Want to know more material grades? Try Patsnap Eureka Material.

Chemical Structure And Molecular Characteristics Of Creatine Phosphate

Creatine phosphate (molecular formula: C₄H₁₀N₃O₅P·Na₂ for the disodium salt) exists as a phosphorylated derivative of creatine, featuring a high-energy phosphate bond between the phosphate group and the guanidino nitrogen of creatine 3. The compound typically manifests in pharmaceutical applications as the disodium salt dihydrate or trihydrate, with the latter exhibiting enhanced aqueous solubility compared to alternative salt forms 3. The phosphorus-nitrogen (P-N) bond energy approximates 43 kJ/mol under physiological conditions, enabling rapid ATP regeneration via the creatine kinase system 6.

Key molecular properties include:

  • Molecular Weight: 327.14 g/mol (disodium salt dihydrate) 5
  • Solubility: Highly soluble in water (>500 mg/mL at 25°C), sparingly soluble in ethanol 7
  • Stability: The P-N bond exhibits pH-dependent hydrolysis, with maximum stability at pH 8.0-9.0 and accelerated degradation below pH 6.0 or above pH 11.0 8
  • Melting Point: Decomposes above 180°C without distinct melting 9

The compound's structural planarity and charge distribution significantly influence crystallization behavior during manufacturing, directly impacting product purity and particle size distribution—critical parameters for pharmaceutical manufacturers 5.

Manufacturing Technologies For Creatine Phosphate Production

Chemical Synthesis Routes: Comparative Analysis

Manufacturers employ three principal chemical synthesis strategies, each presenting distinct advantages and limitations for industrial-scale production.

Phosphoroxychloride Method (Classical Route)

The earliest documented synthesis utilizes phosphoroxychloride (POCl₃) as the phosphorylating agent, reacting directly with creatine under controlled conditions 4. However, this approach suffers from poor yields (typically 35-45%), requires precise temperature control (0-5°C), and generates substantial Na₃PO₄ slurries that resist stirring and cooling, rendering large-scale operation impractical 4. Modern manufacturers have largely abandoned this route due to environmental concerns and economic inefficiency.

Creatinine Phosphoryl Chloride Intermediate Method

Contemporary manufacturers predominantly utilize creatinine (the cyclic anhydride of creatine) as the starting material, converting it to creatinine phosphoryl chloride via reaction with POCl₃ at 105°C for 30 minutes 8,9. The intermediate undergoes alkaline hydrolysis with sodium hydroxide solution to yield creatine phosphate disodium salt. This route offers several manufacturing advantages:

  • Improved overall yield (65-75% from creatinine) 8
  • Reduced POCl₃ consumption (approximately 45-fold molar excess versus creatine-based routes) 9
  • Simplified purification via crystallization from ethanol-water mixtures 5
  • Scalable reaction conditions compatible with standard pharmaceutical equipment 7

Critical process parameters include maintaining reaction temperature at 0-10°C during hydrolysis, pH adjustment to 8.0-9.0 using glacial acetic acid or hydrochloric acid, and controlled ethanol addition (typically 5-7 volumes relative to aqueous phase) to induce crystallization 5,8.

Chlorophosphoric Acid Method (Barium-Free Process)

An innovative barium-free synthesis route involves initial conversion of POCl₃ to chlorophosphoric acid (H₂PO₃Cl) via controlled hydrolysis at 0-10°C, followed by reaction with S-methylisothiourea sulfate to generate phosphorylated S-methylisothiourea, which subsequently reacts with sarcosine to yield creatine phosphate 10. This method eliminates heavy metal contamination risks, reduces environmental impact through gaseous byproducts, and achieves yields exceeding 70% 10. The approach represents a significant advancement for manufacturers prioritizing regulatory compliance and sustainability.

Enzymatic Synthesis: Biocatalytic Production

Enzymatic phosphorylation employing creatine kinase (CK) offers a biomimetic alternative, utilizing ATP and 3-phosphoglyceric acid as phosphate donors in the presence of aqueous muscle extract 4. While this method theoretically provides high specificity and mild reaction conditions, commercial implementation faces substantial challenges:

  • High cost of purified creatine kinase enzyme (approximately $2,000-5,000 per kg) 4
  • Requirement for expensive phosphoenolpyruvate or ATP cofactors 4
  • Complex downstream purification to remove protein contaminants 4
  • Limited scalability due to enzyme stability constraints 4

Currently, only one Chinese manufacturer (Jilin Yinglian Biotechnology) operates enzymatic production at commercial scale, primarily serving niche markets willing to pay premium pricing for "bio-identical" products 10. Most manufacturers continue to favor chemical synthesis for economic viability.

Quality Control Parameters And Analytical Standards For Manufacturers

Purity Specifications And Impurity Profiling

Pharmaceutical-grade creatine phosphate disodium salt must meet stringent purity criteria, typically requiring ≥97.0% assay by HPLC (calculated on anhydrous basis) according to Chinese Pharmacopoeia 2010 Edition 9. Advanced manufacturing processes incorporating multi-stage recrystallization achieve purities exceeding 99.0% 7,9.

Critical impurities requiring quantification include:

  • Residual Creatinine: Should not exceed 0.5% w/w, as it indicates incomplete hydrolysis during synthesis 8
  • Inorganic Phosphate: Limit ≤0.3% w/w, arising from P-N bond hydrolysis during processing 5
  • Heavy Metals: Total heavy metal content must remain below 10 ppm, with specific limits for barium (<5 ppm) in products synthesized via barium salt intermediates 7
  • Chloride Ion: Residual chloride from POCl₃ or HCl neutralization should not exceed 0.2% w/w 8

Manufacturers employ ion-exchange chromatography using 732-type cation exchange resin to remove metallic impurities and improve product purity from crude yields of 85-90% to refined products exceeding 97% 8.

Particle Size Distribution And Crystal Morphology

Product crystallinity and particle size distribution critically influence pharmaceutical processing characteristics, particularly tableting behavior and dissolution kinetics. Optimal manufacturing processes yield well-defined crystalline particles with:

  • Mean Particle Size: 50-150 μm (D50 value by laser diffraction) 5
  • Particle Size Distribution: D90/D10 ratio <3.0, indicating narrow distribution 5
  • Crystal Habit: Prismatic or needle-like morphology with aspect ratio 2:1 to 4:1 9

Manufacturers control crystal characteristics through manipulation of supersaturation ratio, cooling rate during crystallization (typically 0.5-2°C/hour), and ethanol addition rate (0.5-1.0 volumes/hour) 5,7. Triple recrystallization protocols, involving sequential dissolution in purified water, activated carbon decolorization, and ethanol-induced crystallization, produce pharmaceutical-grade material with superior crystal uniformity 5.

Moisture Content And Hydrate Form Stability

Creatine phosphate disodium salt exists in multiple hydrate forms (anhydrous, dihydrate, trihydrate), with moisture content significantly affecting stability and handling properties. Pharmaceutical specifications typically require:

  • Water Content: 9.0-11.0% w/w for dihydrate form (corresponding to theoretical 9.9%) 5
  • Loss On Drying: ≤11.0% when dried at 105°C for 4 hours 9

Manufacturers employ vacuum drying at 40-60°C to achieve target moisture levels while minimizing thermal degradation 5,7. The trihydrate form, though exhibiting enhanced aqueous solubility, presents challenges in maintaining consistent hydration state during storage, necessitating controlled humidity packaging (<30% RH) 3.

Industrial-Scale Manufacturing Process Optimization

Reaction Engineering And Process Intensification

Commercial manufacturers optimize creatine phosphate production through systematic control of reaction parameters and equipment design. Key process intensification strategies include:

Temperature Control Protocols

The creatinine-POCl₃ condensation reaction requires precise temperature management: initial heating to 105°C for 30 minutes to drive ring-opening and phosphorylation, followed by rapid cooling to 30±5°C to prevent over-reaction and tar formation 8,9. Manufacturers employ jacketed reactors with automated temperature control (±2°C precision) and efficient heat transfer surfaces (>150 W/m²·K) to maintain thermal uniformity across batch sizes ranging from 50 kg to 500 kg 9.

The subsequent hydrolysis step demands even tighter temperature control (0-5°C) to minimize P-N bond cleavage and maximize yield 5,8. Industrial implementations utilize plate heat exchangers or internal cooling coils to remove the substantial exothermic heat of neutralization (approximately 58 kJ/mol NaOH) while maintaining reaction temperature within specification 7.

Solvent Recovery And Environmental Sustainability

Excess POCl₃ (typically 400-450 g per 10 g creatinine charge) undergoes vacuum distillation recovery at 30±5°C, achieving >95% solvent recovery for recycle 8,9. Recovered POCl₃ requires purification via fractional distillation (b.p. 105.8°C) to remove phosphoric acid and chlorinated byproducts before reuse 9.

Ethanol employed in crystallization (typically 5-7 volumes relative to aqueous phase) is recovered via vacuum distillation from mother liquors, with recovered ethanol meeting ≥95% purity specification for recycle 5,7. Integrated solvent recovery reduces raw material costs by approximately 30-40% and minimizes environmental discharge 10.

Continuous Manufacturing Considerations

While batch processing dominates current commercial production, emerging continuous manufacturing technologies offer potential advantages in process control, footprint reduction, and quality consistency. Continuous approaches under development include:

  • Microreactor-based phosphorylation with residence times of 5-15 minutes versus batch times of 30-60 minutes 9
  • Continuous crystallization using mixed-suspension mixed-product removal (MSMPR) crystallizers to achieve consistent particle size distribution 5
  • Inline spectroscopic monitoring (FTIR, Raman) for real-time quality control and process adjustment 7

However, regulatory validation requirements and capital investment costs currently limit widespread adoption of continuous manufacturing for creatine phosphate production.

Applications Of Creatine Phosphate: Market Segments For Manufacturers

Cardiovascular Therapeutics And Myocardial Protection

Creatine phosphate serves as a first-line myocardial protective agent in cardiovascular medicine, with clinical efficacy demonstrated in acute myocardial infarction, heart failure, and cardiac surgery applications 10. The compound functions by:

  • Rapidly replenishing intracellular ATP pools via the creatine kinase shuttle system, maintaining cellular energy homeostasis during ischemic stress 6
  • Stabilizing mitochondrial membrane potential and reducing oxidative stress through direct antioxidant effects 3
  • Modulating calcium homeostasis and preventing calcium overload-induced cardiomyocyte death 6

Pharmaceutical manufacturers supply creatine phosphate as lyophilized powder for reconstitution (typical dosage: 1-2 g per vial) or as ready-to-use intravenous solutions (10-20 mg/mL in physiological saline) 5. Clinical dosing regimens typically involve 1-2 g administered twice daily via slow intravenous infusion over 30-60 minutes 10.

The cardiovascular therapeutics segment represents the largest market for creatine phosphate manufacturers, with annual global consumption estimated at 15-20 metric tons of active pharmaceutical ingredient 10. Key manufacturers serving this segment include Italian producer Bioenergy (Schiapparelli brand), Japanese manufacturer Kyowa Hakko, and Chinese producers including Jiangsu Hi-Stone Pharmaceutical and Zhongshan Belling Biotechnology 5,7.

Sports Nutrition And Performance Enhancement

Creatine phosphate and its analogs (particularly cyclocreatine and phosphocyclocreatine) find application in sports nutrition formulations targeting enhanced athletic performance and accelerated recovery 2,3. The disodium salt trihydrate form exhibits superior aqueous solubility compared to creatine monohydrate, enabling higher-concentration beverage formulations (up to 50 g/L) without grittiness or precipitation 3.

Manufacturers targeting the sports nutrition segment must address several formulation challenges:

  • Stability In Acidic Beverages: The P-N bond undergoes rapid hydrolysis below pH 5.0, limiting application in fruit-flavored sports drinks 2. Encapsulation technologies using shellac coatings or enteric polymers (e.g., polyvinylpyrrolidone) protect creatine phosphate from premature hydrolysis and extend shelf life to >24 months 2.
  • Taste Masking: Creatine phosphate exhibits bitter, metallic taste notes requiring masking via sweetener systems (sucralose, acesulfame-K) or flavor encapsulation 2.
  • Bioavailability Optimization: Formulation with dicalcium phosphate and biodegradable polymers enhances oral bioavailability by promoting controlled release in the small intestine, where alkaline pH favors stability 2.

The sports nutrition segment, while smaller than pharmaceutical applications (estimated 3-5 metric tons annual consumption), commands premium pricing ($150-250 per kg versus $80-120 per kg for pharmaceutical grade) due to stringent quality requirements and specialized formulation needs 2.

Neuropharmacology And Neuroprotection Research

Emerging research applications explore creatine phosphate and analogs (cyclocreatine, phosphocyclocreatine, 3-guanidinopropionic acid) as potential therapeutics for neurodegenerative diseases, including transmissible spongiform encephalopathies (TSEs), Alzheimer's disease, and Parkinson's disease 6. The neuroprotective mechanisms involve:

  • Modulation of brain creatine kinase isoforms (BB-CK, mitochondrial CK) to enhance neuronal energy metabolism 6
  • Interference with prion protein misfolding through stabilization of native protein conformations 6
  • Reduction of oxidative stress and mitochondrial dysfunction in neurodegenerative disease models 6

Manufacturers supplying research-grade creatine phosphate and analogs for neuropharmacology applications must provide:

  • High Chemical Purity: ≥99.5% by HPLC with comprehensive impurity profiling 6
  • Endotoxin Control: <0.5 EU/mg for in vivo research applications 6
  • Analog Availability: Cyclocreatine, phosphocyclocreatine (dilithium or disodium salts), guanidinoacetate, and 3-guanidinopropionic acid with documented synthesis routes 3,6

This segment remains primarily research-focused, with limited commercial production (estimated <500 kg annual global consumption), but represents a high-value opportunity for specialized manufacturers capable of producing diverse creatine analogs 6.

Regulatory Compliance And Safety Considerations For Manufacturers

Pharmacopeial Standards And Registration Requirements

Creatine phosphate disodium salt appears in multiple national pharmacopeias, with manufacturers required to demonstrate compliance with applicable monographs:

  • Chinese Pharmacopoeia (ChP 2010, 2015, 2020 Editions): Specifies identification tests (infrared spectroscopy, chemical reactions), assay by HPLC (≥97.0% on anhydrous basis), and limits for related substances, heavy metals, and residual solvents 9,10
  • European Pharmacopoeia (Ph. Eur.): Includes monograph for creatine phosphate disodium salt with similar specifications to ChP, plus additional requirements for bacterial endotoxins (<0.5 EU/mg) 1
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
AlzChem AGSports nutrition supplements and performance enhancement products requiring stable creatine delivery with extended shelf life.Creatine Protein MatrixDeveloped creatine protein matrix formulation with enhanced stability and bioavailability through protein binding technology, eliminating water absorption issues in conventional creatine products.
BYRD EDWARD ANutritional supplements for muscle performance enhancement and neuromuscular disorder treatment requiring controlled release and moisture protection.Creatine Ethyl Ester Controlled Release FormulationOral formulation combining creatine ethyl ester with dicalcium phosphate and biodegradable polymers, achieving improved shelf life, taste masking via shellac coating, and controlled release properties with particle size 20-60 mesh.
AMIRA INC.Oncology therapeutics for tumor growth inhibition and cancer treatment requiring enhanced solubility and stability of creatine phosphate analogs.Phosphorylcyclocreatine Disodium Salt TrihydrateDeveloped phosphorylcyclocreatine disodium salt trihydrate with superior aqueous solubility compared to dilithium dihydrate form, featuring more stable P-N bond for antitumor applications and tumor growth inhibition.
Jiangsu Hi-Stone Pharmaceutical Co. Ltd.Cardiovascular therapeutics for myocardial protection in acute myocardial infarction, heart failure, and cardiac surgery applications.Creatine Phosphate Disodium SaltThree-stage recrystallization process achieving high purity (≥97%), uniform particle size distribution, complete crystal morphology, and low impurity content through optimized temperature control and ethanol crystallization.
Zhongshan Belling Bio Technology Co. Ltd.Pharmaceutical-grade myocardial protective agents for clinical cardiovascular applications requiring heavy metal-free formulations and high safety standards.High Purity Creatine Phosphate SodiumNovel synthesis method via creatinine phosphoryl chloride-carboxylic acid mixed anhydride intermediate, achieving high purity with no heavy metal residue, simplified purification steps, and shortened production cycle.
Reference
  • Creatine protein matrix and method for manufacturing the same
    PatentActiveEP2926669B1
    View detail
  • Oral formulation of creatine derivatives and method of manufacturing same
    PatentInactiveUS20070071815A1
    View detail
  • Creatine phosphate, creatine phosphate analogs, and uses therefor
    PatentInactiveAU1994060979A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png